New Delhi: India has so far reported approximately cases of 8,848 mucormycosis or black fungus, one of the rapidly spreading infections observed in those recovering from Covid-19.
Taking note of the increasing numbers, the Central government has emphasised upon expediting the allocation of vials of Amphotericin-B, a key drug to treat raging mucormycosis.
In this direction, the Union minister of chemicals and fertilisers D.V. Sadananda Gowda has announced an allocation of 23,680 additional vials of Amphotericin-B.
The minister also informed that the allocation has been made based on total number of patients which is approximately 8,848 across the country.
Gujarat (5,800) and Maharashtra (5,090) have been allocated the maximum number of the additional Amphotericin-B vials followed by Andhra Pradesh (2,310), Madhya Pradesh (1,830), Rajasthan (1,780), Karnataka (1,270).
Gujarat has reported maximum of 2,281 mucormycosis cases followed by Maharashtra (2,000), Andhra Pradesh (910), Madhya Pradesh (720) Rajasthan (700), Karnataka (5,00), Haryana (250), Delhi (197), Punjab (95), Chhattisgarh (87), Bihar (56), Tamil Nadu (40), Kerala (36), Jharkhand (27), Odisha (15), Goa (12) and Chandigarh (8).
Mucormycosis is a serious but rare fungal infection caused by a group of molds called mucormycetes that has been developing in Covid-19 patients. The fungal disease is commonly being observed in patients who were given steroids for a long time, who have been hospitalised for a long time, were on oxygen support or ventilator, faced poor hospital hygiene or those who have been taking medication for other illnesses such as diabetes.
If not treated on time, the black fungus infection can turn fatal. The Covid medications can leave the body weak and low on immunity. They can also escalate the blood sugar levels in both diabetics and non-diabetic Covid-19 patients.
Follow this link to join our WhatsApp group: Join Now
Be Part of Quality Journalism |
Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast. |
| ACT NOW |
| MONTHLY | Rs 100 |  |
| YEARLY | Rs 1000 | |
| LIFETIME | Rs 10000 | |
